Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TREAT-UTI study
2025-520622-38-00Phase 3Authorised
- Sponsor
- IRCCS Burlo Garofolo
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of amoxicillin + clavulanate in urinary tract infection (UTI) (2 arms), sponsored by IRCCS Burlo Garofolo. Primary endpoint: Rate of infection recurrence within 30 days after end of therapy. Planned start Feb 2026; status: authorised.
02
Drugs
amoxicillin + clavulanate
03
Conditions
urinary tract infection (UTI)
Beyond the preview
Go deeper on 2025-520622-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520622-38-00.